Our laboratory focuses on the biology of myeloid disease, including acute myeloid leukemia, myelodysplasia, myeloproliferative neoplasms, and MDS/MPN overlap syndrome. Understanding how to attack therapeutic liabilities in myeloid malignancies via investigation of biomarkers of response, and novel model development is central to our ethos.  The laboratory develops therapy from these investigations and studies the biology and conditions of response to these therapies on human cells (primary patient samples) in the hopes of advancing them quickly to the clinic.  Our mission statement is: To develop the best therapy as quickly as possible for the appropriate patients.  This mission drives our inquiry into fundamental questions of myeloid biology and the interaction between hematopoietic cells and their environs, our search for meaningful biomarkers of response, and our decisions to develop new therapy in areas of considerable need.